2022
Physician response to COVID-19-driven telehealth flexibility for opioid use disorder.
Beetham T, Fiellin DA, Busch SH. Physician response to COVID-19-driven telehealth flexibility for opioid use disorder. The American Journal Of Managed Care 2022, 28: 456-463. PMID: 36121359, DOI: 10.37765/ajmc.2022.89221.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCOVID-19HumansOpioid-Related DisordersPandemicsPhysiciansRetrospective StudiesTelemedicineUnited StatesConceptsOpioid use disorder treatmentCOVID-19 pandemicEarly COVID-19 eraOpioid use disorderUse disorder treatmentOUD treatmentTelehealth useUse disordersPhysician responsesTelehealth effectivenessDisorder treatmentTelehealth technologyPhysiciansTelehealthCOVID-19 eraTelehealth regulationsCOVID-19Administrative dataMost respondentsTreatmentRetrospective usePandemicSurvey participationPerceptions of effectivenessRespondents' use
2019
Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study.
Beetham T, Saloner B, Wakeman SE, Gaye M, Barnett ML. Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study. Annals Of Internal Medicine 2019, 171: 1-9. PMID: 31158849, PMCID: PMC7164610, DOI: 10.7326/m18-3457.Peer-Reviewed Original ResearchConceptsBuprenorphine treatmentBuprenorphine prescribersBuprenorphine prescriptionsFirst visitHeroin useActive heroin useBuprenorphine-naloxone treatmentCurrent heroin useOpioid use disorderOpioid-related mortalityReal-world accessClinician typeBuprenorphine inductionPayer statusNew appointmentsHigh burdenBuprenorphine accessFirst appointmentMedicaid coverageUse disordersPatientsDrug abusePrescribersMedicaidNational Institute